Latvian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
amyloidosis/protease
Saite tiek saglabāta starpliktuvē
Lappuse 1 no 50 rezultātiem
Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
TECHNICAL FIELD
The invention generally relates to the diagnosis and treatment of Alzheimer's disease. More specifically, it relates to the characterization and use of materials related to amyloid protein deposits associated with Alzheimer's disease, and to a specific DNA sequence encoding a novel
Amyloid precursor protein protease
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
Alzheimer's disease is a degenerative disorder of the human brain. Clinically, it appears as a progressive dementia. Its histopathology is characterized by degeneration of neurons, gliosis, and the abnormal deposition of proteins in the brain. Proteinaceous deposits (called "amyloid") appear as
Proteases causing abnormal degradation of amyloid .beta.-protein precursor
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
This invention relates to treatment of Alzheimer's disease.
The brains of persons having Alzheimer's disease and Down's syndrome and, to a far lesser extent, the brains of normal aged persons exhibit abnormal extracellular proteinaceous deposits, termed amyloid. Amyloid deposits are thought to be
Proteases causing degradation of amyloid .beta.-protein precursor
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
This invention was made during the course of work supported in part by the U.S. Government, and the Government has certain rights in the invention.
This invention relates to treatment of Alzheimer's disease.
The brains of persons having Alzheimer's disease and Down's
Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE PRESENT INVENTION
The present invention is directed to novel compounds and also to methods of treating at least one condition, disorder, or disease associated with amyloidosis using such compounds.
BACKGROUND OF THE PRESENT INVENTION
Amyloidosis refers to a collection of conditions,
Amyloid precursor protein protease
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
A peptide of 42 to 43 residues known as the .beta.-amyloid peptide (.beta./A4) has been implicated in Alzheimers's disease and Down's syndrome. Researchers hypothesize that abnormal accumulation of this 4 Kd protein in the brain is due to cleavage of a larger precursor
(Hydroxyethyl)ureas as inhibitors of alzheimer's .beta.-amyloid production
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION
The invention relates to methods and compositions for inhibiting certain aspartyl proteases. More particularly it relates to methods and compounds for inhibiting the enzymatic activity of secretases involved in converting amyloid precursor protein to amyloid-.beta. peptide.
Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
Alzheimer's disease (AD) is the most common form of both senile and presenile dementia in the world and is recognized clinically as relentlessly progressive dementia that presents with increasing loss of memory, intellectual function and disturbances in speech (Merritt,
Catalytic monoclonal antibodies with protease activity for selective lysis of protein component of plaques aggregates pathological conditions
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
The present invention relates to catalytic monoclonal antibodies, in particular with protease activity, for the selective lysis of the protein component of plaques and aggregates related to pathological conditions.
Alzheimer's Disease
Alzheimer's disease (AD) is a degenerative disease which affects
Gamma three protease
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
STATEMENT REGARDING FEDERALLY-SPONSORED R&D
Not applicable.
REFERENCE TO MICROFICHE APPENDIX
Not applicable.
FIELD OF THE INVENTION
The present invention is directed to the field of Alzheimer's disease. In particular, the present invention provides a novel aspartyl protease involved in the
Protease inhibitor peptides
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
The plasma, or serine, proteases of the blood contact system are known to be activated by interaction with negatively charged surfaces. For example, tissue injury during surgery exposes the vascular basement membrane, causing interaction of the blood with collagen, which
Protease inhibitor peptides
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
The plasma, or serine, proteases of the blood contact system are known to be activated by interaction with negatively charged surfaces. For example, tissue injury during surgery exposes the vascular basement membrane, causing interaction of the blood with collagen, which
Protease inhibitor peptides
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
The plasma, or serine, proteases of the blood contact system are known to be activated by interaction with negatively charged surfaces. For example, tissue injury during surgery exposes the vascular basement membrane, causing interaction of the blood with collagen, which
Protease inhibitor peptides
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
BACKGROUND OF THE INVENTION
The plasma, or serine, proteases of the blood contact system are known to be activated by interaction with negatively charged surfaces. For example, tissue injury during surgery exposes the vascular basement membrane, causing interaction of the blood with collagen, which
Amyloidin protease and uses thereof
Rakstu tulkošanu var veikt tikai reģistrēti lietotāji
Ielogoties Reģistrēties
FIELD OF THE INVENTION
The present invention relates to purification of mammalian enzymes and more particularly to the purification of human amyloidin protease, the identification of the gene encoding the protease, the identification of inhibitors of this protease, and various uses
Vispilnīgākā ārstniecības augu datu bāze, kuru atbalsta zinātne
- Darbojas 55 valodās
- Zāļu ārstniecības līdzekļi, kurus atbalsta zinātne
- Garšaugu atpazīšana pēc attēla
- Interaktīva GPS karte - atzīmējiet garšaugus atrašanās vietā (drīzumā)
- Lasiet zinātniskās publikācijas, kas saistītas ar jūsu meklēšanu
- Meklēt ārstniecības augus pēc to iedarbības
- Organizējiet savas intereses un sekojiet līdzi jaunumiem, klīniskajiem izmēģinājumiem un patentiem
Ierakstiet simptomu vai slimību un izlasiet par garšaugiem, kas varētu palīdzēt, ierakstiet zāli un redziet slimības un simptomus, pret kuriem tā tiek lietota.
* Visa informācija ir balstīta uz publicētiem zinātniskiem pētījumiem
